Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. New issue in AttgeNO
Mandate

New issue in AttgeNO

May 02, 2018 M&A

The Swedish pharmaceutical research company AttgeNO has performed a new issue of shares.

AttgeNO works on the development of new pharmaceuticals which expand blood vessels. Supernitro (PDNO) is a new, patented pharmaceutical candidate for treatment of acute and life-threatening high blood pressure in the lungs, which, can arise for example in connection with heart surgery and may result in death. The capital generated as a result of the new issue of shares is intended to give AttgeNO an opportunity to perform clinical Phase 1 studies during 2019.

AttgeNO was advised by partner Johan Winnerblad.

Related

Vinge advises Stendörren in connection with issuance of green capital securities

 Vinge has advised Stendörren Fastigheter AB in connection with its issuance of green capital securities in an amount of SEK 400 million (within a framework of SEK 800 million).
May 07, 2026

Vinge represents Cinven in connection with the acquisition of Ongoing Warehouse

 Vinge has represented the international private equity firm Cinven in connection with its acquisition of Ongoing Warehouse.
May 06, 2026

Vinge advises Fazer in connection with its acquisition of Aroma

 Fazer has entered into an agreement to acquire Konfektyrfabriken Aroma AB, a Swedish confectionery manufacturer known for its classic candy products such as Geléhallon, Hallonbåtar, Röda Hjärtan and Gräddkola. The acquisition strengthens Fazer's position in the Swedish confectionery market, particularly within pick & mix, packed candy, and seasonal products. The acquisition is subject to customary regulatory approvals.
May 06, 2026